公开(公告)号：US10016426B2

公开(公告)日：2018-07-10

申请号：US15408814

申请日：2017-01-18

Applicant: Resverlogix Corp.

Inventor： Narmada R. Shenoy

IPC: A61K31/517 ,  A61K9/48 ,  A61K9/16

Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

公开(公告)号：US20160346291A1

公开(公告)日：2016-12-01

申请号：US14912517

申请日：2014-08-21

Applicant: Kenneth Eugene LEBIODA

Inventor： Kenneth Eugene LEBIODA

IPC: A61K31/5377 ,  A61K31/4375 ,  A61K31/517 ,  A61K31/519 ,  A61K31/505 ,  A61K31/47

CPC classification number: A61K31/5377 ,  A61K31/40 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/4704 ,  A61K31/505 ,  A61K31/517 ,  A61K31/519 ,  A61K2300/00

Abstract: The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through-co-administration of therapeutically effective amounts of a compound of Formula I or a pharmaceutically acceptable salt thereof and rosuvastatin or pravastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin. The invention further provides compositions comprising a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of or pitavastatin or a pharmaceutically acceptable salt of rosuvastatin or pitavastatin.

Abstract translation: 本发明包括治疗和/或预防心血管，胆固醇和脂质相关疾病（包括动脉粥样硬化）的方法，其通过共同给予治疗有效量的式I化合物或其药学上可接受的盐和罗苏伐他汀或普伐他汀或药物 罗沙伐他汀或匹伐他汀的可接受的盐。 本发明还提供了包含治疗有效量的式I化合物或其药学上可接受的盐和治疗有效量的匹伐他汀或罗沙伐他汀或匹伐他汀的药学上可接受的盐的组合物。

公开(公告)号：US09238640B2

公开(公告)日：2016-01-19

申请号：US13257082

申请日：2010-03-16

Applicant: Henrik C. Hansen

Inventor： Henrik C. Hansen

IPC: A61K31/54 ,  A61K31/535 ,  C07D401/04 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  C07D239/91 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D409/10 ,  C07D471/04

CPC classification number: C07D239/91 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D409/10 ,  C07D409/12 ,  C07D471/04

Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

Abstract translation: 公开了可用于调节白细胞介素-6（IL-6）和/或血管细胞粘附分子-1（VCAM-1）的表达的新型化合物及其在治疗和/或预防心血管和炎症疾病中的用途 和相关疾病状态，例如动脉粥样硬化，哮喘，关节炎，癌症，多发性硬化，牛皮癣和炎症性肠病以及自身免疫性疾病。 还公开了包含新化合物的组合物，以及它们的制备方法。

公开(公告)号：US20130108672A1

公开(公告)日：2013-05-02

申请号：US13665147

申请日：2012-10-31

Applicant: Resverlogix Corp.

Inventor： Narmada R. Shenoy

IPC: A61K31/517 ,  A61P35/00 ,  A61P9/00 ,  A61P25/28 ,  A61P29/00 ,  A61P3/04 ,  A61K9/14 ,  A61P3/10

CPC classification number: A61K31/517 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1652 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

Abstract: The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

Abstract translation: 本公开涉及新型固体药物制剂及其制备方法。 本公开还部分地提供了使用药物制剂调节载脂蛋白AI（ApoA-I）表达的方法及其用于治疗和预防心血管疾病和相关疾病状态的用途，包括胆固醇或脂质 - 相关疾病，例如动脉粥样硬化。

公开(公告)号：US20090259048A1

公开(公告)日：2009-10-15

申请号：US12369296

申请日：2009-02-11

Applicant: Norman C.W. Wong ,  Joseph E.L. Tucker ,  Henrik C. Hansen ,  Fabrizio S. Chiacchia ,  David McCaffrey

Inventor： Norman C.W. Wong ,  Joseph E.L. Tucker ,  Henrik C. Hansen ,  Fabrizio S. Chiacchia ,  David McCaffrey

IPC: C07D405/14

CPC classification number: C07D213/64 ,  A61K31/05 ,  A61K31/055 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/216 ,  A61K31/265 ,  A61K31/352 ,  A61K31/353 ,  A61K31/357 ,  A61K31/382 ,  A61K31/435 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/4433 ,  A61K31/465 ,  A61K31/47 ,  A61K31/536 ,  C07C37/003 ,  C07C37/055 ,  C07C37/18 ,  C07C39/14 ,  C07C39/15 ,  C07C39/21 ,  C07C43/23 ,  C07C46/00 ,  C07C49/83 ,  C07C49/835 ,  C07C50/32 ,  C07C205/22 ,  C07C311/29 ,  C07C317/22 ,  C07C327/28 ,  C07D213/65 ,  C07D213/80 ,  C07D213/89 ,  C07D215/233 ,  C07D217/16 ,  C07D217/22 ,  C07D217/24 ,  C07D265/22 ,  C07D311/30 ,  C07D311/32 ,  C07D311/36 ,  C07D311/60 ,  C07D319/20 ,  C07D335/06 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D471/04 ,  C07D491/052

Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

Abstract translation: 本公开提供了上调载脂蛋白A-I（ApoA-I）表达的非天然存在的多酚化合物。 所公开的组合物和方法可用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关疾病，例如动脉粥样硬化。

公开(公告)号：US20090029987A1

公开(公告)日：2009-01-29

申请号：US11990162

申请日：2006-07-28

Applicant: Norman C.W. Wong ,  Henrik C. Hansen ,  Fabrizio S. Chiacchia ,  Jan O. Johansson

Inventor： Norman C.W. Wong ,  Henrik C. Hansen ,  Fabrizio S. Chiacchia ,  Jan O. Johansson

IPC: A61K31/5377 ,  C07D491/052 ,  A61P29/00 ,  C07D405/04 ,  C07D215/20 ,  C07D217/12 ,  C07D471/04 ,  A61K31/496 ,  C07D217/22 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/472 ,  A61K31/47

CPC classification number: C07D471/04 ,  A61K31/352 ,  A61K31/435 ,  A61K31/4353 ,  C07D215/233 ,  C07D217/16 ,  C07D217/22 ,  C07D217/24 ,  C07D405/04 ,  C07D413/04 ,  C07D491/04

Abstract: The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states.

Abstract translation: 本发明涉及可用于抑制哺乳动物中VCAM-1表达，MC​​P-1表达和/或SMC增殖的多酚样化合物。 所公开的化合物可用于调节炎性病症的标志物，包括血管炎症，以及用于治疗和预防炎性和心血管疾病及相关疾病状态。

公开(公告)号：US20210361656A1

公开(公告)日：2021-11-25

申请号：US17335960

申请日：2021-06-01

Applicant: Resverlogix Corp.

Inventor： Henrik C. HANSEN

IPC: A61K31/517 ,  A61K31/4375 ,  A61K31/472 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5377 ,  C07D217/24 ,  C07D239/91 ,  C07D279/02 ,  C07D401/04 ,  C07D405/04 ,  A61K31/44 ,  A61K31/47 ,  A61K31/497 ,  A61K31/535 ,  A61K31/54 ,  C07D403/12 ,  C07D471/04 ,  C07F7/18 ,  A61K31/695 ,  A61L29/16 ,  A61L31/16

Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.

公开(公告)号：US20210070716A1

公开(公告)日：2021-03-11

申请号：US16951701

申请日：2020-11-18

Applicant: Resverlogix Corp.

Inventor： Henrik C. Hansen

IPC: C07D239/91 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D409/10 ,  C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D409/12

Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

公开(公告)号：US10882828B2

公开(公告)日：2021-01-05

申请号：US16159002

申请日：2018-10-12

Applicant: Resverlogix Corp.

Inventor： Henrik C. Hansen

IPC: A61K31/551 ,  C07D239/91 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D409/10 ,  C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D409/12

Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

公开(公告)号：US20190119222A1

公开(公告)日：2019-04-25

申请号：US16159002

申请日：2018-10-12

Applicant: Resverlogix Corp.

Inventor： Henrik C. HANSEN

IPC: C07D239/91 ,  C07D409/12 ,  A61K31/517 ,  C07D471/04 ,  C07D409/10 ,  C07D403/12 ,  C07D403/10 ,  C07D403/04 ,  C07D401/12 ,  C07D401/10 ,  C07D401/04 ,  A61K31/551 ,  A61K31/55 ,  A61K31/5377 ,  A61K31/519 ,  C07D401/14

Abstract: Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.